This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
DosingDosingDosing ScheduleDose ModificationsAboutAboutStudy MethodologyEfficacy & SafetyEfficacy & Safety Progression-free Survival & Objective Response RateCNS EfficacyGuidelinesSafety TablesSafety Overview

Menu

Close

DosingDosingDosing ScheduleDose ModificationsTherapy ManagementTherapy ManagementHyperlipidaemiaOedemaILD/PneumonitisCNS EffectsSummarySupport & ServicesSupport & ServicesSummary of Prescribing InformationDownloadable ResourcesEvents & WebinarsVideosUseful Links

LORBRIQUA® (lorlatinib) is indicated for the treatment of adult patients with ALK+ metastatic NSCLC.1

CNS Efficacy

IC-ORR by BICR2

  

Lorlatinib demonstrated 82% IC-ORR in patients with measurable brain metastases at baseline

   Adapted from Shaw AT, et al. 2020.    82% IC Response Rate With LORBRIQUA® in 17 Patients With Measurable Brain Metastases at Baseline (BICR Assessed)2,†

  

Example

   

IC Time to Progression by BICR2,3

   

  

Adapted from Shaw AT, et al. 2020.

   


*OR >1 indicates better outcome for lorlatinib relative to crizotinib.
LORBRIQUA®, n=17; crizotinib, n=13 with measurable CNS lesions at baseline as assessed by the BICR.

    

ALK+, anaplastic lymphoma kinase-positive; BICR, blinded independent central review; CI, confidence interval; CNS, central nervous system; CR, complete response; DoR, duration of response; ESMO, European Society for Medical Oncology; HR, hazard ratio; IC, intracranial; IC-ORR, intracranial objective response rate; NE, not evaluable; NR, not reached; NSCLC, non-small cell lung cancer; OR, odds ratio; PR, partial response.


References:

Lorbriqua. Local product document. Pfizer; 2021. Version LPDLOR082021.Shaw AT, Bauer TM, de Marinis F, et al. CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.Solomon B, Bauer TM, De Marinis F, et al. LBA2 - Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): results of the phase 3 CROWN study. Paper presented at: European Society for Medical Oncology (ESMO) Virtual Congress; September 19-21, 2020. Accessed March 15, 2016. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/lorlatinib-vs-crizotinib-in-the-first-line-treatment-of-patients-pts-with-advanced-alk-positive-non-small-cell-lung-cancer-nsclc-results-of-th

   

Please click the Prescribing Information link to view the safety and adverse events information of LORBRIQUA®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.​​​​​​

   

PP-LOR-IND-0129 June 2022

Efficacy & Safety

Example


American Cancer Society

The American Cancer Society funds and conducts research, shares expert information and provides support for patients who have been affected by cancer.

Learn moreLoading


Lung Cancer Foundation of America

The Lung Cancer Foundation of America aims to improve the survivorship of patients with lung cancer through the funding of transformative science.

Learn moreLoading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-LOR-IND-0129

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​